Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Disease
• Genetics

Background:

• Apolipoprotein (apo)C-III is a key regulator of plasma triglyceride (TG) levels.
• Hypertriglyceridemia (HTG) increases risks for pancreatitis and atherosclerotic cardiovascular disease (ASCVD).

Purpose of the Study:

• To discuss apoC-III as a therapeutic target for HTG.
• To describe olezarsen's pharmacodynamics, pharmacokinetics, and metabolism.
• To report on clinical trial findings for olezarsen, a liver-directed APOC3 antisense oligonucleotide (ASO).

Main Methods:

• Review of clinical trial data for olezarsen.
• Analysis of olezarsen's efficacy in reducing TG levels.
• Assessment of olezarsen's safety profile, including liver enzymes and thrombocytopenia.

Main Results:

• Olezarsen reduces TG levels by approximately 50% in patients with extreme and moderate HTG.
• Olezarsen does not cause clinically meaningful elevations in liver enzymes or thrombocytopenia.
• Ongoing Phase III trials (CORE, CORE2, ESSENCE) will provide further insights.

Conclusions:

• Olezarsen is a promising therapeutic agent for HTG, targeting apoC-III.
• Further research is needed to confirm its ASCVD risk reduction benefits.
• Upcoming trial results will guide future cardiovascular outcomes trials.